CSL Limited CSL
ASX · Australia · Health Technology
AUD 178.24-5.98 (-3.25%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
CSL Seqirus, a business of CSL (ASX: CSL), today announced expanded availability of influenza vaccine in the United States following the successful completion of its 2026/27 manufacturing campaign.
BOSTON, September 29, 2026--Sware, Inc., the company behind the Res_Q, the AI-powered validation platform, and provider of GxP compliance solutions, today announced the appointment of Mark Hill to its Board of Directors.
CSL Seqirus has secured a multi-year extension of its UK government Advance Purchase Agreement for pandemic influenza vaccines.
CSL Canada has expanded public reimbursement for ANDEMBRY® (garadacimab), its once-monthly hereditary angioedema prophylaxis, across Quebec, Alberta and key federal programs, following strong Phase 3 trial data and a nomination for the 2026 Prix Galien USA Award. This broader public access in Canada highlights how CSL’s high-value specialty therapies can convert scientific progress into wider real-world usage and reimbursement. We’ll now explore how ANDEMBRY®’s expanded public reimbursement...
CSL Canada announced today that public access to ANDEMBRY® (garadacimab) is expanding in Canada, with reimbursement now available for eligible patients in Quebec and Alberta, as well as through the federal Non-Insured Health Benefits (NIHB) Program and Veterans Affairs Canada (VAC).
CSL Seqirus, a business of CSL (ASX: CSL; USOTC: CSLLY), today announced publication of pivotal Phase 3 study results for its MF59®-adjuvanted cell-based higher-dose quadrivalent influenza vaccine (aQIVc) in The Lancet Infectious Diseases, marking an important milestone in the evolution of influenza prevention for older adults.1
This article first appeared on GuruFocus. CSL Ltd (CSLLY) recently announced a total dividend of $0.41 per share, with the ex-dividend date set for 2026-09-10. This includes a $0.41 per share cash dividend payable on 2026-10-09.
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). ANDEMBRY is approved in over 40 countries for the prevention of HAE attacks in adult and pediatric patients aged 12 years and older.
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the revocation of the European Union (EU) marketing authorisation for TAVNEOS® (avacopan). TAVNEOS is a treatment for adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), which are the main forms of ANCA-associated vasculitis. TAVNEOS is indicated for use in combi
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has appointed Dr Charmaine Gittleson and Michael Kotsanis as non-executive directors as part of a board enhancement process aimed at supporting the company’s clinical-stage cell therapy strategy. Both appointments take effect from June 30,...
CSL Canada is proud to announce the first Canadian patient has received HEMGENIX® (etranacogene dezaparvovec), a one-time hemophilia B gene therapy, at London Health Sciences Centre (LHSC). This milestone marks a significant advancement in hemophilia B care, reflecting how clinical innovation and health system collaboration are enabling real-world access to gene therapy for eligible patients in Canada.
CSL now expects weaker full-year revenue and profit as plasma, China pricing, and Vifor pressures weigh on performance.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CSL (ASX:CSL) has outlined a restructuring plan that includes separating its Seqirus influenza vaccine business into a standalone entity. The company is also planning workforce reductions and the closure of selected plasma collection centres. Management has linked these steps to prolonged margin pressures and operational challenges across parts of the business. For holders of ASX:CSL, this update arrives after a difficult period for the share price, with the stock at A$124.84 and showing...
CSLLY vs. ACAD: Which Stock Is the Better Value Option?
CSLLY vs. ARGX: Which Stock Is the Better Value Option?
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.